{
    "nctId": "NCT04216576",
    "briefTitle": "A Study of the Use of Text Message Reminders to Take Palbociclib",
    "officialTitle": "Oral Self-Management of Palbociclib (Ibrance\u00ae) Using Mobile Technology",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "Accuracy rate of medication self-administration",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with a breast cancer diagnosis who are initiating therapy on palbociclib (Ibrance)\n* \\>/= 18 years of age\n* Able to speak, read and write English\n* Willingness and ability to send and receive text messages with intervention app\n* Own a mobile telephone \"smartphone\" with text messaging capabilities. Only iPhone or Android operating systems support OhMD Application\n* Criteria applicable for both Control and Intervention groups\n* Flip-phones do not support OhMD Application and thus ineligible to participate\n* Initiation palbociclib (Ibrance) for the first time, either as monotherapy or in conjunction with other medication such as Lstrozole (Femara) or Fulvestrant (Faslodex)\n\nExclusion Criteria:\n\n* History of taking palbociclib (Ibrance)\n* Patients whose caregivers coordinate their health care",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}